Sarcopenia Clinical Trials 2023

Sarcopenia Clinical Trials 2023

Sarcopenia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in sarcopenia clinical trials today.

Sarcopenia Clinical Trials

Here are the 6 most popular medical studies for sarcopenia

Popular filter options for sarcopenia trials

Sarcopenia Clinical Trials With No Placebo

View 29 sarcopenia medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to sarcopenia

What are the top hospitals conducting sarcopenia research?

In the battle against sarcopenia, a condition characterized by the loss of muscle mass and strength often associated with aging, several top hospitals are leading the charge in clinical trials. The U of Maryland, Baltimore Professional Schools IRB has emerged as a key player with two active sarcopenia trials and a total of two trials conducted thus far. Their commitment to understanding this condition began in 2015, marking their first recorded sarcopenia trial. Similarly, Beth Israel Deaconess Medical Center in Boston is making significant strides with two ongoing sarcopenia studies and a history of two completed trials since embarking on their research journey just recently in 2021.

Notably joining this mission is the Translational Research Institute for Metabolism and Diabetesf Maryland, Baltimore Professional Schools IRB has emerged as a key player with two active sarcopenia trials and a total of two trials conducted thus far. Their commitment to understanding this condition began in 2015, marking their first recorded sarcopenia trial. Similarly, Beth Israel Deaconess Medical Center in Boston is making significant strides with two ongoing sarcopenia studies and a history of two completed trials since embarking on their research journey just recently in 2021.

Notably joining this mission is the Translational Research Institute for Metabolism and Diabetes in Orlando. With an equal number of active and all-time sarcopenia trials (two each), they have been investigating this condition since 2014—a testament to their dedication towards unraveling its complexities.

Further expanding geographical diversity within these efforts is the University of Oregon located in Eugene. Although having fewer active trials with just one currently underway, they hold great potential for advancing our knowledge about sarcopenia through their sole prior study initiated back in 2017.

Finally, breaking new ground on Canadian soil is Toronto's Goldring Center for High Performance Sport where they are actively conducting one cutting-edge sarcopenia trial—paving the way for breakthroughs that can positively impact future treatment options. Their inaugural contribution to research was documented only recently during 2023.

By pushing boundaries and exploring innovative approaches, these esteemed institutions offer hope to individuals living with or at risk of developing sarcopenia. Through collaboration between researchers across different locations, we inch closer toward discovering effective interventions that can combat muscle loss associated with aging—and ultimately improve quality of life for countless individuals around the world facing this challenge

Which are the best cities for sarcopenia clinical trials?

When it comes to sarcopenia clinical trials, several cities in the United States are at the forefront of research and development. Boston, Massachusetts leads the way with 6 active trials exploring interventions like exercise groups, low-soluble fiber diets, and LPCN 1148. Baltimore, Maryland closely follows with 5 ongoing studies focusing on interventions such as MRP+HPRO+NMES+UC and aerobic exercise training. Dallas, Texas also contributes to this field with 2 active trials investigating LPCN 1148 among other potential treatments. Other cities involved in sarcopenia clinical trials include Orlando, Florida and Aurora, Colorado, Maryland closely follows with 5 ongoing studies focusing on interventions such as MRP+HPRO+NMES+UC and aerobic exercise training. Dallas, Texas also contributes to this field with 2 active trials investigating LPCN 1148 among other potential treatments. Other cities involved in sarcopenia clinical trials include Orlando, Florida and Aurora, Colorado. These cities offer individuals affected by sarcopenia access to cutting-edge research that paves the way for improved care options and a better quality of life.

Which are the top treatments for sarcopenia being explored in clinical trials?

Sarcopenia, the age-related decline in muscle mass and strength, is a condition that researchers are actively exploring for potential treatments. Among the top contenders are exercise training and exercise itself, with each having two active trials and an impressive track record of all-time sarcopenia trials—five for exercise training since 2011 and seventeen for exercise since 2009. Another intriguing option being investigated is a low-soluble fiber dietf all-time sarcopenia trials—five for exercise training since 2011 and seventeen for exercise since 2009. Another intriguing option being investigated is a low-soluble fiber diet, which has one active trial thus far after its recent listing in 2023. As these clinical trials progress, they offer hope for combating sarcopenia and improving quality of life for individuals affected by this condition.

What are the most recent clinical trials for sarcopenia?

Exciting advancements are being made in the field of sarcopenia, with recent clinical trials offering promising possibilities for treatment. One such trial focuses on HB HIIT + CoQ10, a combination therapy that has entered Phase 3. This regimen aims to address the muscle loss associated with sarcopenia by incorporating high-intensity interval training (HIIT) and coenzyme Q10 (CoQ10). Another notable study is examining the effectiveness of zoledronic acid in combating sarcopenia during its Phase 4 stage. Additionally, MYMD-1 at a dosage of 600mg is currently under investigation in Phase 2 as a potential treatment option for this condition. Lastly, LPCN 1148 has shown potential benefits against sarcopenia and is progressing through its Phase 2 trial stages. These initiatives hold promise for individuals impacted by sarcopenia and offer hope for improved outcomes moving forward.

What sarcopenia clinical trials were recently completed?

Recently, several clinical trials focusing on sarcopenia have been completed, shedding light on potential strategies to combat this age-related condition. Notably, a trial sponsored by the University of Sao Paulo investigated the effects of resistance training combined with nutritional supplementation and concluded in November 2021. Another noteworthy study was conducted by the National Institute on Aging and examined the impact of hormone therapy in older adults; it reached completion in August 2021. These recent advancements highlight ongoing efforts to understand and address sarcopenia's complex nature, offering hope for improved treatments and interventions for individuals affected by this debilitating condition.